CTLA4 and sarcoma: Nivolumab (anti-PD-1 antibody) monotherapy and in combination with ipilimumab (anti-CTLA-4 antibody) was evaluated by the phase II Alliance trial in locally advanced, unresectable, or metastatic sarcomas.